Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy

Brazilian Journal of Infectious Diseases

Volumn 16, Issue 4, 2012, Pages 351-356

  Tuon, Felipe F ^a   Gortz, Lucas W ^a   Rocha, Jaime L ^b  

^a HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA   (Brazil)

^b Division of Microbiology   (Brazil)

Author keywords

Antibiotic resistance; Imipenem; Meropenem; Pseudomonas aeruginosa; Risk factor

Indexed keywords

CARBAPENEM; CEPHALOSPORIN; ERTAPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLONE;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BLOODSTREAM INFECTION; CARBAPENEM PSEUDOMONAS AERUGINOSA BACTEREMIA; CARBAPENEM RESISTANT PSEUDOMONAS AERUGINOSA; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG USE; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LABORATORY TEST; LEUKOCYTE COUNT; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PSEUDOMONAS AERUGINOSA; RISK FACTOR;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; CARBAPENEMS; CASE-CONTROL STUDIES; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS;

EID: 84864364922     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2012.06.009     Document Type: Article

References (25)

1. Morrison A.J., Wenzel R.P. Epidemiology of infections due to Pseudomonas aeruginosa. Rev Infect Dis 1984, 6(Suppl 3):S627-S642.
2. Lister P.D., Wolter D.J., Hanson N.D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009, 22:582-610.
3. Parkins M.D., Gregson D.B., Pitout J.D., Ross T., Laupland K.B. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection 2010, 38:25-32.
4. Kerr K.G., Snelling A.M. Pseudomonas aeruginosa: a formidable and ever-present adversary. J Hosp Infect 2009, 73:338-344.
5. Okeke I.N. Poverty and root causes of resistance in developing countries. Antimicrobial resistance in developing countries 2010, Springer, London. 1 ed. A.J. Sosa, D.K. Byarugaba, C.F. Amabile-Cuevas, P.R. Hsue, S. Kariuk, I. Okeke (Eds.).
6. Scheetz M.H., Hoffman M., Bolon M.K., et al. Morbidity associated with Pseudomonas aeruginosa bloodstream infections. Diagn Microbiol Infect Dis 2009, 64:311-319.
7. Baumgart A.M., Molinari M.A., Silveira A.C. Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz J Infect Dis 2010, 14:433-436.
8. Kiffer C., Hsiung A., Oplustil C., et al. MYSTIC Brazil Group. Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003. Braz J Infect Dis 2005, 9:216-224.
9. Wirth F.W., Picoli S.U., Cantarelli V.V., et al. Metallo-beta-lactamase-producing Pseudomonas aeruginosa in two hospitals from southern Brazil. Braz J Infect Dis 2009, 13:170-172.
10. Scheffer M.C., Gales A.C., Barth A.L., Carmo Filho J.R., Dalla-Costa L.M. Carbapenem-resistant Pseudomonas aeruginosa: clonal spread in southern Brazil and in the state of Goias. Braz J Infect Dis 2010, 14:508-509.
11. Strateva T., Yordanov D. Pseudomonas aeruginosa-a phenomenon of bacterial resistance. J Med Microbiol 2009, 58:1133-1148.
12. Aloush V., Navon-Venezia S., Seigman-Igra Y., Cabili S., Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006, 50:43-48.
13. York M. Aerobic Bacteriology. Clinical microbiology procedures handbook 2004, ASM Press, New York. 2 ed. H.I. Isenberg (Ed.).
14. Performance standards for antimicrobial susceptibility testing 2010, Clinical and Laboratory Standards Institute, CLSI, Pennsylvania.
15. Tuon F.F., Rymsza A.M., Penteado-Filho S.R., Pilonetto M., Arend L.N., Levin A.S. Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter?. J Infect 2011, 62:246-249.
16. Tuon F.F., Bianchet L.C., Penteado-Filho S.R. Epidemiology of extended spectrum beta-lactamase producing Enterobacter bacteremia in a Brazilian hospital. Rev Soc Bras Med Trop 2010, 43:452-454.
17. Johnson L.E., D'Agata E.M., Paterson D.L., et al. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis 2009, 11:227-234.
18. Kang C.I., Kim S.H., Park W.B., et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 2005, 11:68-74.
19. Falagas M.E., Koletsi P.K., Kopterides P., Michalopoulos A. Risk factors for isolation of strains susceptible only to polymyxin among patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2006, 50:2541-2543.
20. Suárez C., Peña C., Tubau F., et al. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections. J Infect 2009, 58:285-290.
21. Zavascki A.P., Barth A.L., Goldani L.Z. Nosocomial bloodstream infections due to metallo-beta-lactamase-producing Pseudomonas aeruginosa. J Antimicrob Chemother 2008, 61:1183-1185.
22. McGregor J.C., Rich S.E., Harris A.D., et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 2007, 45:329-337.
23. Tuon F.F., Kruger M., Terreri M., Penteado-Filho S.R., Gortz L. Klebsiella ESBL bacteremia-mortality and risk factors. Braz J Infect Dis 2011, 15:594-598.
24. Osih R.B., McGregor J.C., Rich S.E., et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2007, 51:839-844.
25. Koprnova J., Beno P., Korcova J., et al. Bacteremia due to Pseudomonas aeruginosa: results from a 3-year national study in the Slovak Republic. J Chemother 2005, 17:470-476.